Take a look at the fellows currently participating in the SPARK program. Click the (+) icon for additional information about the teams and technologies.
Oral Biofilm Disruption and Selective Inhibition of S. mutans Biofilms
Carrying out toxicity and biocompatibility studies of a novel bio-organic dental coating. The novelty of the coating is that it mechanically disrupts cariogenic-biofilm formation via visible light activation.
Complete efficacy and PK studies of a diphtheria toxin IL2-CCR4 immunotoxin for cutaneous T-cell lymphoma and potentially other Treg-IL2 cancers.
Repositioning neurokinin-1 receptor (NK-1R) antagonists as antiviral agents against human herpesviruses
Repurposing NK-1R antagonists as antiviral agents for neuronal infection of varicella zoster virus. Zoster vaccines do not support neuronal infection or patient’s under 50 y/o.
Novel inhibitors of trimethylamine lyase for the treatment of rheumatoid arthritis
Developing novel small molecule therapeutics for rheumatoid arthritis. This is a novel non-immunosuppressive therapeutic strategy by drugging the human microbiome.
Team Project: Methods
for understanding functional heterogeneity among single cells
Developing a kit that can measure functional activity of various enzyme classes or specific target at the single cell level. Technology provides actual functional activity in a single cell workflow.
Team Project: An ultra-compact CT scanner for point-of-care imaging
Developing a small, portable CT scanner for brain scans. The CT scanner uses flat panel X-ray detectors as well as scatter mitigation and associated algorithms.
Multifunctional Nanoclusters for Detection and Treatment of Bladder Cancer
Developing a ‘theranostic’ nanoparticle to diagnose and treat superficial EGFR+ bladder cancer. These nanoparticles, which are coated with gold nanorods, will target cancer lesions with anti-EGFR mAb. The nanorods will ablate lesions upon light stimulation.
LPL activators as novel therapeutics for neurological conditions
Validated a novel target, lipoprotein lipase, involved in neuronal development and maintenance. Team is developing LPL activators for treating neurodegenerative conditions.
iSense: A First-in-Class Therapy for Insufficient Pupil Dilation
Reformulating dexmedetomidine into an eye drop to treat patients whose eyes do not dilate well. This eye drop integrates into standard pre-treatment procedures prior to cataract surgery.